|2.||Cardiovascular Diseases (Cardiovascular Disease)
|3.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
|1.||Yamagishi, Sho-ichi: 19 articles (01/2015 - 02/2004)|
|2.||Matsui, Takanori: 13 articles (01/2015 - 01/2006)|
|3.||Belcaro, G: 13 articles (12/2012 - 10/2001)|
|4.||Cesarone, M R: 13 articles (12/2012 - 10/2001)|
|5.||Takeuchi, Masayoshi: 13 articles (05/2012 - 11/2002)|
|6.||Yamamoto, Hiroshi: 11 articles (03/2012 - 03/2003)|
|7.||Nakamura, Kazuo: 10 articles (11/2008 - 02/2005)|
|8.||Yamamoto, Yasuhiko: 9 articles (03/2012 - 03/2003)|
|9.||Yamagishi, S: 9 articles (01/2007 - 08/2000)|
|10.||Imaizumi, Tsutomu: 8 articles (11/2008 - 01/2005)|
|1.||Insulin (Novolin)FDA Link
01/08/2013 - "An improved therapeutic approach to combat diabetic vascular complications might include blocking mechanisms of injury as well as promoting protective or regenerating factors, for example by enhancing the action of insulin-regulated genes in endothelial cells, promoting gene programs leading to induction of antioxidant or anti-inflammatory factors, or improving the sensitivity to vascular cell survival factors. "
12/01/2002 - "In conclusion insulin appears to regulate shedding or clearance of VAP-1, and an increase in sVAP-1 because of absolute or relative insulin deficiency may be directly involved in the pathogenesis of diabetic angiopathy."
09/01/2011 - "The aim of the present study was to evaluate the improvement of diabetic microangiopathy in patients suffering from this condition since at least five years, and whose disease was managed without insulin. "
11/01/2004 - "The study confirms the crucial role of intensive insulin therapy and systematic patients' education concerning the disease in maintaining a good metabolic control and thus reducing the risk of diabetic vascular complications."
10/01/1991 - "Factors associated with diabetic microangiopathy: a study of 157 type I (insulin-dependent) diabetic patients."
|2.||Blood Glucose (Blood Sugar)IBA
04/15/1988 - "Tight control of blood sugar in close association with antihypertensive treatment reducing blood pressure to a lower normal limit, possibly with agents that specifically decrease glomerular capillary hydraulic pressure are the corner stone in protection against progression of the diabetic angiopathy."
02/01/2015 - "Pre-clinical and clinical studies suggest that poor control of blood glucose fluctuations contributes to progression of diabetic vascular complications. "
01/01/2009 - "These results suggest that moderate elevations in blood glucose, as seen in our lean GK model of type 2 diabetes, promote resistance artery remodeling resulting in increased medial thickness, whereas addition of a high-fat diet contributes to diabetic vascular disease predominantly by impairing vascular reactivity in the time frame used for this study. "
07/01/1999 - "Blood glucose control as well as blood pressure control are important in the prevention of diabetic vascular complications as evidenced by large-scale interventional studies."
05/01/1995 - "From this study, the glycemic threshold to prevent the onset and the progression of diabetic microangiopathy is indicated as follows; HbA1c < 6.5%, FBG < 110 mg/dl, and 2-h post-prandial blood glucose concentration < 180 mg/dl."
|3.||Advanced Glycosylation End ProductsIBA
05/01/2000 - "Cross-link breakers seem to be effective in preventing or reversing accumulation of advanced glycation end-products in blood vessels and have the potential to play a part in the treatment of diabetic vascular complications."
07/01/2009 - "Many studies have demonstrated association between advanced glycation end products (AGEs) and diabetic angiopathy. "
03/28/1997 - "This study was undertaken to determine whether and how advanced glycation end products (AGE), senescent macroproteins accumulated in various tissues under hyperglycemic states, cause angiogenesis, the principal vascular derangement in diabetic microangiopathy. "
09/01/2015 - "Advanced glycation end products (AGEs) play an important role in the pathogenesis of diabetic vascular complications. "
01/01/2015 - "Advanced glycation end-products (AGEs) are thought to play a major role in the pathogenesis of diabetic vascular complications. "
10/01/1981 - "The improved technique reported here should facilitate study of the platelet hyperaggregation co-factor and the pathophysiology of diabetic microangiopathy."
01/01/2001 - "We found a significant reduction in lung diffusion capacity for carbon monoxide (DL(CO)) in the group of patients with other signs of diabetic microangiopathy (p < 0.005) and a significative correlation between DL(CO )and the grade of albuminuria (r = -0.83, p < 0.001). "
05/01/1988 - "Impaired carbon monoxide gas transfer has been demonstrated in patients with insulin-dependent diabetes mellitus (IDDM), but no relationship has been documented between impairment of gas transfer and the presence of other clinical evidence of diabetic microangiopathy. "
10/01/2013 - "The data indicated that co-administration of grape seed extract and exercise training had more significant effects than exercise training or grape seed extract alone; this may constitute a convenient and inexpensive therapeutic approach to diabetic vascular complications."
01/01/1999 - "In 20 patients with diabetic angiopathy of lower extremities and purulent-necrotic complications, in whom the diagnosis of chronic syndrome of disseminated intravascular blood coagulation (DIC-syndrome), preparation vobenzym (Mucos Pharma & Co, Germany) was applied. "
|5.||Plasminogen Activators (Plasminogen Activator)IBA
05/01/2000 - "Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy."
01/01/2006 - "Elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) are observed in patients with obesity, hypertension and diabetes, and several observations suggest that PAI-1 mediates diabetic vascular complications. "
04/01/2011 - "The glucagon like peptide-1 receptor (GLP-1R) agonist liraglutide attenuates induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression in human vascular endothelial cells (hVECs) in vitro and may afford protection against endothelial cell dysfunction (ECD), an early abnormality in diabetic vascular disease. "
11/01/2008 - "(1) In patients with type 1 diabetes without microangiopathy and with good metabolic control, fibrinogen and tissue plasminogen activator antigen concentrations and changes in the activity of plasminogen activator inhibitor-1 are similar to those found in patients with a normal pregnancy; (2) the marked decrease in platelet count in patients with type 1 diabetes during pregnancy may be an additional source of plasminogen activator inhibitor-1; and (3) during pregnancy, diabetic microangiopathy leads to a greater increase of tissue plasminogen activator antigen concentration as a marker of endothelial cell injury."
|6.||telmisartan (Micardis)FDA Link
01/01/2014 - "Telmisartan improved the structural and functional indices of aortic stiffening induced by untreated STZ-diabetes, demonstrating the importance of ARBs in the therapeutic approach to diabetic vascular complications."
07/08/2011 - "Our data provided the first evidence indicating that PPARγ activity of telmisartan contributed to the protective effects of telmisartan against diabetic vascular complication. "
07/08/2011 - "We hypothesized that telmisartan protects against diabetic vascular complications, through PPARγ activation. "
07/08/2011 - "Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity."
01/01/2008 - "Since the pathophysiological crosstalk between the AGEs-RAGE system and angiotensin II has also been associated with diabetic microangiopathy, we examined here whether and how telmisartan, a unique angiotensin II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, could inhibit the AGEs-elicited endothelial cell injury by suppressing RAGE expression in vitro. "
02/01/2009 - "Tight glycemic control may be beneficial in preventing the pathologic development of capillary BM thickening and FN overexpression in retinal and renal tissues, two target tissues of diabetic microangiopathy."
07/01/2000 - "In the present study we conclude that microalbuminuria is not a good marker for diabetic microangiopathy defined as renal and retinal involvement, although its presence prompt us to watch more frequently the ocular fundus in diabetic patients."
01/01/1994 - "This study has shown that SM cell loss, a hitherto unrecognised feature of diabetic microangiopathy, accompanies pericyte loss in the retinal circulation of diabetic dogs."
07/01/2010 - "Recent literature on the epidemiology and impact of diabetic microangiopathy (maculopathy) on visual function was reviewed to provide a comprehensive overview of the functional and socioeconomic consequences of diabetic retinal microangiopathy and new therapeutic strategies. "
07/01/2003 - "Retinal diabetic microangiopathy follows much the same principles, be it that microvascular proliferation is a distinctive element in the retina. "
01/07/1988 - "Previous studies have suggested that the sulphonylurea hypoglycaemic agent gliclazide has specific effects in inhibiting platelet aggregation, and other haemorrheological effects that could be beneficial in preventing diabetic microangiopathy. "
03/01/1987 - "Thus, this study did not detect a reversal of the parameters measured and does not support an action of gliclazide on diabetic microangiopathy, independent of its hypoglycaemic action."
03/01/1987 - "This study has attempted to document a specific haemovascular action of gliclazide on the reversal of early diabetic microangiopathy. "
08/01/2003 - "In addition, gliclazide MR shows the ability to inhibit key mechanisms in diabetic angiopathy, independently of glycemic control."
10/01/2000 - "In diabetes, therefore, where increased glycation and oxidation are fundamental to the pathogenesis of diabetic vascular disease, agents such as gliclazide with its antioxidant activities may have an enhanced therapeutic role."
|9.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
10/01/1986 - "Trial of repeated low-dose aspirin in diabetic angiopathy."
10/01/1982 - "[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid]."
05/15/1979 - "In the present survey the hitherto existing reports from literature are critically summarized, taking into particular consideration the per ipheral angioorganopathies and first informations on an own study concerning the prophylaxis of the diabetic angiopathy with Micristin are given. "
03/01/2012 - "In the latter setting, it was concluded that "schedules of aspirin which may suffice in normals are not effective in patients with diabetic angiopathy, presumably because these patients have a high rate of entry of new platelets into the circulation". "
03/01/2012 - "In 2004 an editorial article on the so-called "aspirin resistance" and diabetic angiopathy as related to platelet turnover was published by one of us. "
|10.||Pentoxifylline (Trental)FDA LinkGeneric
01/01/1985 - "The results of this study suggest that pentoxifylline is an effective drug for the long-term treatment of diabetic vascular complications and that it may also possibly depress or prevent the progress of the disease."
04/01/1981 - "[Trials of trental in treatment of diabetic angiopathy (author's transl)]."
01/01/1982 - "[Treatment of diabetic angiopathy with pentoxifylline]."
01/01/1978 - "[Therapeutic effect of Trental in diabetic angiopathy]."
01/01/1983 - "The purpose of our study was to verify the possibility of obtaining a reduction in the erythrocyte filtration rate and an improvement in the O2 tissue uptake in twenty patients suffering from insulin-dependent diabetes mellitus and diabetic angiopathy, randomly divided in two groups receiving pentoxifylline (1,200 mg/day for 30 days) or a placebo solution, respectively. "
|1.||Laser Therapy (Surgery, Laser)
10/01/1996 - "A course of magnetic-laser therapy results in significant reduction of concentration of the lipid oxidation products as one of the pathogenetic mechanisms of diabetic microangiopathies, normalization of immunologic reactivity as well as attenuation of clinical manifestations of hemocirculatory disorders in the lower extremities and improvement of parameters of thermo- and rheovasography."
10/01/1996 - "[The medical effect of magnetic-laser therapy in patients with diabetic angiopathies of the lower extremities]."
01/01/1996 - "Prolonged normovolemic hemodilution (PNH) was shown to be highly effective in treatment of 87 patients with diabetic angiopathies of the lower extremity vessels. "
01/01/1996 - "[Experience in using prolonged normovolemic hemodilution in patients with diabetic angiopathies of the vessels of the lower extremities]."
12/01/1993 - "Patients with diabetic microangiopathy were studied by laser-Doppler flowmetry--measuring skin blood flux at rest (RF) and the venoarteriolar response (VAR) and evaluating the rate of ankle swelling (RAS) to study capillary filtration. "
09/01/2002 - "Our data show a significant increase in skin circulation due to athermic laser irradiation in patients with diabetic microangiopathy and point to the possibility of inducing systemic effects."
09/01/2002 - "We therefore investigated such a potential systemic effect of low-intensity laser irradiation on skin blood circulation in patients with diabetic microangiopathy. "
09/01/2002 - "Systemic effects of low-intensity laser irradiation on skin microcirculation in patients with diabetic microangiopathy."
10/01/2001 - "Fifty patients with diabetic microangiopathy were studied by laser Doppler flowmetry (measuring skin blood flow at rest) (RF) and the venoarteriolar response (VAR), by transcutaneous PO2 and PCO2 measurements, and by capillary permeability evaluation (rate of ankle swelling [RAS]). "
12/01/1993 - "Microcirculatory effects of elastic stockings in diabetic microangiopathy: a 24-week study."
01/01/1990 - "However further studies, treating with elastic compression more patients for longer periods, are needed to confirm the positive effects of elastic stockings in improving diabetic microangiopathy and in slowing down its rate of progression."
12/01/1993 - "Elastic stockings seem to be useful in diabetic microangiopathy improving microcirculatory parameters and decreasing capillary filtration and oedema. "
01/01/1992 - "Seventy four patients were advised to wear elastic stockings and 75 were kept as controls with the aim of evaluating the effects of stockings on the evolution of diabetic microangiopathy. "
01/01/1992 - "Elastic stockings in diabetic microangiopathy. "
08/31/1991 - "The effects of pancreas transplantation on diabetic microangiopathy are difficult to evaluate in these patients who often have very advanced complications, but the first data are encouraging. "
10/01/1990 - "Does combined kidney and pancreas transplantation reverse functional diabetic microangiopathy?"
02/01/1989 - "Evidence for reversibility of diabetic microangiopathy following pancreas transplantation."
06/01/1988 - "Pancreas transplantation: curative therapeutic approach to diabetic microangiopathy?"
10/01/1987 - "Changes of diabetic microangiopathy after pancreas transplantation."